Lilly(Eli) & Company
Eli Lilly is a major American pharmaceutical company engaged in diabetes, obesity, oncology, immunology, and neuroscience. Its growth is currently driven by tirzepatide (Mounjaro, Zepbound), which has become one of the most dynamic treatments on the market, as well as Trulicity, Jardiance, and the oncology drug Verzenio. The company benefits from a differentiated portfolio of blockbusters, extensive expertise in insulins, and a strong pipeline that enhances medium-term visibility. Its competitive advantage relies on clinical innovation, industrial mastery, and strong structural demand in the cardio-metabolic space. The main risks remain regulatory pressure, increased competition, and a marked dependence on flagship molecules.
Price history of Lilly(Eli) & Company
Price history of Lilly(Eli) & Company
Performance & Momentum
Lilly Bolsters Oncology With Ajax Therapeutics Deal
Eli Lilly has agreed to acquire Ajax Therapeutics in a deal worth up to $2.3 billion. The transaction will strengthen its hematology portfolio with a JAK2 inhibitor program for myelodysplastic syndrome/myelofibrosis, and fits into a broader oncology expansion strategy following another deal announced earlier this month. The market is taking the diversification move relatively well, especially as several analysts have reiterated positive views on the stock. In the near term, the transaction may support the group's growth profile, even if it adds acquisition costs and does not immediately change operating results.
Strategic Analysis
Lilly(Eli) & Company • 2026
Eli Lilly is a leading U.S. pharmaceutical company, positioned in high-value therapeutic franchises in diabetes, obesity, immunology, oncology and neuroscience. Its model is built around innovative drugs with strong commercial potential, with a proven ability to turn clinical breakthroughs into durable growth drivers. The company stands out for a portfolio of blockbusters and a pipeline that provides visibility above the sector average.
- Leadership in cardiometabolic care with treatments that have become market benchmarks
- Rich pipeline and strong clinical execution, supported by favorable recent data in immunology and new growth drivers
- Ability to monetize innovation thanks to strong structural demand and high industrial capacity
- Rich valuation that leaves little room for operational or regulatory disappointment
- Significant dependence on a few flagship molecules, which increases concentration risk if competition intensifies or launches slow
Momentum remains very strong and reflects a favorable underlying trend, with share-price performance that mirrors confidence in the growth of the portfolio and pipeline visibility. The latest news flow reinforces this positive bias: FDA approval of Foundayo supports the innovation narrative, while strong data on EBGLYSS and advances in oral GLP-1 and Olumiant suggest several catalysts that could broaden the growth engine beyond already dominant products. For investors, this confirms a defensive-growth leader stance, but with a high bar for execution and upcoming regulatory milestones.
Similar stocks to Lilly(Eli) & Company
Recent News
Lilly(Eli) & Company
Eli Lilly rallies on FDA approval for Foundayo
1 month agoEli Lilly has secured FDA approval for Foundayo (orforglipron), a once-daily oral obesity pill for adults who are overweight or obese with comorbidities. The approval marks a major milestone, as a non-injectable treatment with no food or water requirements could significantly broaden access to the GLP-1 market. The U.S. launch is set to begin through LillyDirect and pharmacies, with filings planned in more than 40 countries. This advance strengthens Lilly’s position in cardiometabolic care and boosts expectations for revenue growth, which is supportive for the stock in the short to medium term.
Eli Lilly: Strong EBGLYSS Data
1 month agoEli Lilly presented new four-year data for EBGLYSS in moderate to severe atopic dermatitis. The open-label study shows sustained skin clearance, lasting relief from itching, and a safety profile considered favorable over time. This publication strengthens EBGLYSS’s commercial potential beyond the obesity theme alone and supports the group’s investment case. In a still mixed market backdrop for the stock, this clinical progress could improve investor sentiment in the short term.
Eli Lilly Boosts Growth with Oral GLP-1 and Olumiant
2 months agoEli Lilly reports promising results with its oral GLP-1 candidate, orforglipron, showing superior blood sugar and weight reductions in type 2 diabetics compared to competitors. The company has filed regulatory applications in over 40 countries, with U.S. approval expected in Q2 2026, including an obesity indication. Additionally, Eli Lilly and Incyte received a positive EMA opinion for Olumiant targeting adolescents with severe alopecia areata, strengthening their portfolio. These advancements enhance the medium-term growth outlook and may support a positive stock momentum.
Eli Lilly Advances with Key Psoriasis and Obesity Trial
3 months agoEli Lilly reported positive results from its Phase 3b TOGETHER-PsO trial combining Taltz and Zepbound. The study showed significant efficacy in treating both psoriasis and obesity, with 27.1% of patients achieving complete skin clearance. Additionally, the company is expanding its portfolio by acquiring rights to develop clazakizumab, a promising monoclonal antibody. These developments bolster confidence in Lilly's growth prospects on the NYSE.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
